Identification of an Immune Single Cell Transcriptomic Profile of Responder and Non-responder Hepatocellular Carcinoma Patients Treated With Immune-checkpoint Inhibitors

Exclusion Criteria

• •1. Life expectancy of \<12 months due to concomitant diseases
• •2. Active or history of autoimmune disease or immune deficiency on inflammatory chronic diseases
• •3. Ongoing drug abuse
• •4. History of malignancy other than HCC within 3 years prior to study entry with the following exception:
• •1. Completely resected malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate 90%) and without evidence of recurrence for \> 3 years prior to study entry
• •2. adequately treated non-melanoma skin carcinoma or lentigo maligna without evidence of metastases.
• •3. adequately treated carcinoma in situ of the cervix without evidence of recurrence
• •4. localised prostate cancer
• •5. adequately treated non invasive or in situ urothelial cancers
• •5. evidence or history of positive HIV test
• •6. inability to comply with the study protocol, in the investigator's judgment